Transition report pursuant to Rule 13a-10 or 15d-10

Subsequent Events

v3.21.1
Subsequent Events
9 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events

NOTE 15 — SUBSEQUENT EVENTS

 

In February 2021, the Company extended its sponsored research agreement with ULRF for development of several small-molecule RAS interaction inhibitor drug candidates and increased the amount that the Company will reimburse ULRF for sponsored research expenses from $693,000 to approximately $1.4 million (see Note 10).